2-Bromo-LSD Treatment for Treatment-Resistant Depression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for major depressive disorder (MDD) have limited efficacy, with only 50-60% of patients responding to initial therapy and 30-40% failing to achieve symptom resolution with standard antidepressant treatment.
Innovation Solution
Administration of 2-Bromo-LSD or its derivatives as a pharmaceutical composition, formulated in various forms, to treat mental and mood disorders, including MDD, offering therapeutic benefits with minimal toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard antidepressant treatment is used, then treatment coverage is provided, but therapeutic efficacy is limited with only 50-60% of patients responding to initial therapy
Solution Approach 1:
The patent introduces 2-Bromo-LSD, a compound with modified chemical structure (bromo substitution at position 2 of the lysergic acid diethylamide), to change the pharmacological parameters of treatment. This structural modification aims to achieve superior therapeutic efficacy in treatment-resistant depression patients who did not respond to standard antidepressants, thereby resolving the contradiction between limited efficacy and treatment coverage.
2Reliability
If 2-Bromo-LSD is administered to treatment-resistant patients, then therapeutic benefits are achieved, but potential toxicity concerns arise
Solution Approach 1:
The patent specifies precise dosage ranges (10-50 μg, preferably 20-30 μg) and controlled administration protocols for 2-Bromo-LSD to achieve therapeutic benefits while minimizing toxicity. By optimizing the local quality of the treatment (dosage, frequency, patient selection criteria), the patent aims to maximize efficacy in treatment-resistant patients while reducing harmful effects.
Solution Approach 2:
The patent introduces 2-Bromo-LSD as an intermediary substance between standard antidepressant treatment and more aggressive therapeutic interventions. This compound serves as a mediator that can provide therapeutic benefits to treatment-resistant patients with a potentially more favorable safety profile compared to other alternative treatments.
3Adaptability or versatility
If multiple dosage options are provided, then treatment flexibility is improved, but treatment complexity increases
Solution Approach 1:
The patent establishes dynamic dosage adjustment protocols where the dose of 2-Bromo-LSD can be adjusted from 10-50 μg based on patient response and tolerance. This dynamic approach allows treatment flexibility to adapt to individual patient needs while providing clear guidance to manage the complexity of dosage selection.
Data Source
AI summary
Methods using 2-Bromo-LSD or a derivative or salt thereof to treat subjects suffering from mental and/or mood disorders. The 2-Bromo-LSD is provided as a pharmaceutical composition formulated in a variety of manners for resolving symptoms even in subjects who have failed prior therapy. Methods comprise or consist of administering 2-bromolysergic acid diethylamide or a derivative or salt thereof to a subject in need of.